Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this year and face generic competition.

# Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this year and face generic competition. **Read the full article:** [CNBC](https://www.cnbc.com/2026/02/03/merck-mrk-earnings-q4-2025.html) *This article was originally published by CNBC. MoneyWiseInc provides expert curation of the best financial content from trusted sources.*